Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity
Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Stroke, Ischemic
In brief
The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke.
Key facts
- Study ID
- NCT04221256
- Run by
- Burke Medical Research Institute
- People needed
- 0
- Starts
- 2020-03-11
- Expected to finish
- 2021-02-09
- Last updated by the study team
- 2021-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- Contraindications to TMS: epilepsy or other seizure history, ferromagnetic metallic implants in the head, or pacemaker
- Current or history of neurological disorders or brain lesions such as stroke, multiple sclerosis, tumor, traumatic brain injury, spinal cord injury
- Diagnosis of major depressive disorder or other psychiatric disorder
- Currently taking escitalopram or another selective serotonin reuptake inhibitor
- Currently taking or have taken in the past month other medications or supplements that have known interactions with escitalopram or can precipitate serotonin syndrome when taken in combination with escitalopram: monoamine oxidase inhibitors, methylene blue, linezolid, serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort
- Known hypersensitivity to escitalopram or any of its inactive ingredients.
- History of cerebral hemorrhage, gastrointestinal bleeding, or genitourinary bleeding.
- History of prolonged QTc
- Pregnant or breastfeeding
- Social and/or personal circumstances that interfere with the ability to return for all study visits.
- Stroke Patients Inclusion criteria
- Men and women aged 18 years and older.
- Ability to give informed consent.
- History of ischemic stroke
- Exclusion criteria
- Contraindications to TMS: epilepsy or other seizure history, ferromagnetic metallic implants in the head, or pacemaker
- Current or history of neurological disorders or brain lesions such as multiple sclerosis, tumor, traumatic brain injury, spinal cord injury
- Diagnosis of major depressive disorder or other psychiatric disorder
- Currently taking escitalopram or another selective serotonin reuptake inhibitor
- Currently taking or have taken in the past month other medications or supplements that have known interactions with escitalopram or can precipitate serotonin syndrome when taken in combination with escitalopram: monoamine oxidase inhibitors, methylene blue, linezolid, serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort
- Known hypersensitivity to escitalopram or any of its inactive ingredients.
- History of cerebral hemorrhage, gastrointestinal bleeding, or genitourinary bleeding.
- History of prolonged QTc
- Pregnant or breastfeeding
- Social and/or personal circumstances that interfere with the ability to return for all study visits.
Where it is running
- Burke Neurological Institute — White Plains, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.